Talazoparib plus enzalutamide improves progression-free survival in metastatic prostate cancer
1. Progression-free survival was significantly higher in the talazoparib plus enzalutamide group compared to enzalutamide alone. 2. There were no ...
Tag: metastatic castration-resistant prostate cancer
#VisualAbstract: Continued enzalutamide after progression of metastatic prostate cancer improves progression-free survival
1. The median progression-free survival was higher in the enzalutamide vs the placebo group (9.5 months vs 8.3 months) 2. ...
Continued enzalutamide after progression of metastatic prostate cancer improves progression-free survival
1. The median progression-free survival was higher in the enzalutamide vs the placebo group (9.5 months vs 8.3 months). 2. ...
Olaparib improves the quality of life for metastatic castration-resistant prostate cancer patients
1. Olaparib led to a bigger decrease in pain interference and symptomatic skeletal-related events than hormonal drugs. 2. Olaparib demonstrated ...
Ipatasertib plus abiraterone significantly improves survival in patients with PTEN-negative prostate cancer compared to abiraterone alone
1. Ipatasertib-abiraterone treatment significantly improved progression-free survival compared to placebo-abiraterone in patients with PTEN-loss metastatic castration-resistant prostate cancer. 2. Grade ...
Radiolabeled Lutetium-177 offers higher PSA response versus cabazitaxel in metastatic castration-resistant prostate cancer
1. Radiolabeled Lutetium-177 offered greater PSA response versus current standard of care, cabazitaxel. 2. Fewer grade 3-4 adverse events occurred ...